You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ):磷酸奧司他韋幹混懸劑獲得NMPA註冊批准
格隆匯 01-26 20:17

格隆匯1月26日丨樂普醫療(300003.SZ)公佈,下屬公司樂普製藥科技有限公司自主研發的磷酸奧司他韋幹混懸劑正式獲得國家藥品監督管理局(NMPA)註冊批准。奧司他韋是一種作用於神經氨酸酶的抗病毒藥物,通過影響流感病毒的複製過程,從而抑制流感病毒在體內的增殖,減輕症狀。主要用於甲型、乙型流感的治療和預防。磷酸奧司他韋幹混懸劑主要適用於2周及2周齡以上人羣的甲流和乙流治療和1歲及以上人羣的甲流和乙流預防。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account